Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Werewolf Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Werewolf Therapeutics, Inc.’s stock price such as:

• Werewolf Therapeutics, Inc.’s current stock price and volume
• Why Werewolf Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for HOWL from analysts
• HOWL’s stock price momentum as measured by its relative strength

About Werewolf Therapeutics, Inc. (HOWL)

Before we jump into Werewolf Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Want to learn more about Werewolf Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Werewolf Therapeutics, Inc..

Werewolf Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Werewolf Therapeutics, Inc.’s stock price was $0.353.

Werewolf Therapeutics, Inc. is down 29.44% from its previous closing price of $0.500.

During the last market session, Werewolf Therapeutics, Inc.’s stock traded between $0.340 and $0.500. Currently, there are approximately 48.60 million shares outstanding for Werewolf Therapeutics, Inc..

Werewolf Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Werewolf Therapeutics, Inc. Stock Price History

Werewolf Therapeutics, Inc.’s (HOWL) price is currently down 1.89% so far this month.

During the month of July, Werewolf Therapeutics, Inc.’s stock price has reached a high of $0.540 and a low of $0.295.

Over the last year, Werewolf Therapeutics, Inc. has hit prices as high as $2.380 and as low as $0.270. Year to date, Werewolf Therapeutics, Inc.’s stock is down 44.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Werewolf Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Werewolf Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Werewolf Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Werewolf Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Werewolf Therapeutics, Inc. (HOWL) by visiting AAII Stock Evaluator.

Relative Price Strength of Werewolf Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Werewolf Therapeutics, Inc. has a weighted four-quarter relative price strength of -28.00%, which translates to a Momentum Score of 8 and is considered to be Very Weak.

Want to learn more about how Werewolf Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Werewolf Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Werewolf Therapeutics, Inc.’s stock price is $0.353, which is down 29.44% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Werewolf Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.